Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHCR7 | Q9UBM7 | 3/20 | 0.57 |
| ▸ | DRD3 | P35462 | 11/20 | 0.54 |
| ▸ | DRD4 | P21917 | 9/20 | 0.54 |
| ▸ | DRD2 | P14416 | 8/20 | 0.54 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.54 |
| ▸ | DRD1 | P21728 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4112908 | 1.00 | DHCR7 (0.57) | DHCR7DRD3DRD4DRD2TMEM97 | |
| SCHEMBL4117524 | 0.92 | KMT2A (0.49) | DHCR7DRD3DRD4DRD2TMEM97 | |
| SCHEMBL4111106 | 0.90 | DHCR7 (0.42) | DHCR7DRD3DRD4DRD2TMEM97 | |
| SCHEMBL4123258 | 0.83 | KDM4E (0.45) | DRD3DRD4TMEM97DRD1KDM4E | |
| SCHEMBL4111403 | 0.83 | CHRM2 (0.47) | DRD3DRD4TMEM97DRD1KDM4E | |
| SCHEMBL4118261 | 0.82 | DRD2 (0.41) | DRD3DRD4DRD2DRD1CA9 | |
| SCHEMBL4113275 | 0.82 | DRD2 (0.41) | DRD3DRD2DRD1ABCB1 | |
| SCHEMBL4117669 | 0.82 | SLC6A2 (0.44) | ABCB1 | |
| SCHEMBL3048278 | 0.81 | KDM4E (0.67) | DHCR7DRD3DRD4DRD2TMEM97 | |
| SCHEMBL4111986 | 0.80 | PRMT5 (0.47) | DRD3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090075978-A1 | SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS | GRUNENTHAL GMBH (DE) | 2009-03-19 | — | — | US | claimed |
| US-20090075978-A1 | SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS | GRUNENTHAL GMBH (DE) | 2009-03-19 | — | — | US | disclosed |
| EP-1968938-A1 | SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS | Grünenthal GmbH (DE) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007079957-A1 | SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS | Grünenthal GmbH (DE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075978-A1 | SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS | PCCA, PPARA, PTGES | DHCR7 452/4885DRD3 922/4885DRD4 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.